Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 6, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ashwani Verma Initiated (AVDL) at Strong Buy and Held Target at $21 on, Feb 6th, 2024
Ashwani Verma of UBS, Initiated "Avadel Pharmaceuticals plc" (AVDL) at Strong Buy and Held Target at $21 on, Feb 6th, 2024.
Ashwani has made no other calls on AVDL in the last 4 months.
There is 1 other peer that has a rating on AVDL. Out of the 1 peers that are also analyzing AVDL, 0 agree with Ashwani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ashwani
- Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $20 on, Wednesday, December 20th, 2023
